Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
about
Clinical review: bacteremia caused by anaerobic bacteria in childrenShort prereduced anaerobically sterilized (PRAS) biochemical scheme for identification of clinical isolates of bile-resistant Bacteroides speciesLongitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centersComparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.Enhancing effect of lysine combined with other compounds on cephamycin C production in Streptomyces clavuligerus.Survey of Bacteroides fragilis group susceptibility patterns in Canada.Susceptibilities of members of the Bacteroides fragilis group to 11 antimicrobial agentsNational hospital survey of anaerobic culture and susceptibility testing methods: results and recommendations for improvement.Spiral gradient endpoint method compared to standard agar dilution for susceptibility testing of anaerobic gram-negative bacilli.Five-year retrospective epidemiological survey of anaerobic bacteraemia in a university hospital and rewiew of the literature.Occurrence of Bacteroides fragilis enterotoxin gene-carrying strains in Germany and the United States.Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group.
P2860
Q24798485-19E56409-84A1-4892-8C2F-5E637B9ED102Q28331798-7C34B945-95FD-4CF7-AC54-7A0C89313328Q33760528-43AEC088-5BB0-4E85-9D4D-29EDE4B5B4CDQ33980464-6AD9079C-5497-41CD-8FE8-1A3298104385Q35073786-C7435F97-7553-45A3-943B-5FD686A43F79Q35825806-9D1D4113-5DA8-41AF-8350-E7666C3C4E5FQ35900710-6CCBB394-DD7F-40C2-93AB-DD254059416DQ37121958-4A2DA14F-5CA4-4020-8CBE-61A988FE5FE8Q37234463-F231466E-1575-462D-BC84-9B08EAC3D715Q37642134-AF232C39-5A24-45A0-A33C-CDC768517AFAQ39457590-6601CA79-F39F-4DF3-AD1F-078D9AB34D2CQ40087406-A0109DCD-B35D-4D43-AC57-4C05BCE91457
P2860
Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Annual incidence, epidemiology ...... he Bacteroides fragilis group.
@en
Annual incidence, epidemiology ...... he Bacteroides fragilis group.
@nl
type
label
Annual incidence, epidemiology ...... he Bacteroides fragilis group.
@en
Annual incidence, epidemiology ...... he Bacteroides fragilis group.
@nl
prefLabel
Annual incidence, epidemiology ...... he Bacteroides fragilis group.
@en
Annual incidence, epidemiology ...... he Bacteroides fragilis group.
@nl
P2860
P1476
Annual incidence, epidemiology ...... he Bacteroides fragilis group.
@en
P2093
Goldstein EJ
P2860
P304
P407
P577
1988-11-01T00:00:00Z